Viracta Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIRX research report →
Companywww.viracta.com
Viracta Therapeutics, Inc. , a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
- CEO
- Craig R. Jalbert
- IPO
- 2005
- Employees
- 26
- HQ
- Cardiff-by-the-Sea, CA, US
Price Chart
Valuation
- Market Cap
- $388.70K
- P/E
- -0.01
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -0.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -128.57%
- ROIC
- -115.54%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-51,058,000 · -2.58%
- EPS
- $-1.32 · 0.00%
- Op Income
- $-50,693,000
- FCF YoY
- -12.75%
Performance & Tape
- 52W High
- $0.19
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.28
- Avg Volume
- 281.45K
Get TickerSpark's AI analysis on VIRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 25, 24 | ROYSTON IVOR | other | 25,219 |
| Nov 25, 24 | ROYSTON IVOR | other | 25,219 |
| Nov 25, 24 | Pomerantz Roger | other | 9,034 |
| Nov 25, 24 | Pomerantz Roger | other | 9,034 |
| Aug 25, 24 | ROYSTON IVOR | other | 25,219 |
| Aug 25, 24 | ROYSTON IVOR | other | 25,219 |
| Aug 25, 24 | Pomerantz Roger | other | 9,034 |
| Aug 25, 24 | Pomerantz Roger | other | 9,034 |
| Jun 20, 24 | ROYSTON IVOR | other | 50,000 |
| Jun 20, 24 | Borellini Flavia | other | 50,000 |
Our VIRX Coverage
We haven't published any research on VIRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIRX Report →